From the Research
Platelet-rich plasma (PRP) is not currently recommended as a primary treatment for eczema. The standard first-line treatments for eczema include topical corticosteroids (such as hydrocortisone 1% for mild cases or triamcinolone 0.1% for moderate cases), topical calcineurin inhibitors (tacrolimus or pimecrolimus), and good skin care practices including regular use of emollients and avoiding triggers. For more severe cases, phototherapy, oral immunosuppressants like cyclosporine, methotrexate, or biologics such as dupilumab may be used.
Key Points to Consider
- The most recent and highest quality study on eczema treatment is from 2022 1, which focuses on strategies for using topical corticosteroids in children and adults with eczema, but does not mention PRP as a treatment option.
- Another recent study from 2020 2 compares the efficacy and safety of different systemic immunosuppressive treatments for moderate to severe eczema, ranking dupilumab as the most effective biological treatment, but again, does not include PRP in the comparison.
- The mechanism behind eczema involves complex immune dysregulation and skin barrier dysfunction, which current evidence does not suggest PRP adequately addresses.
- Patients with eczema should consult with a dermatologist to develop an appropriate treatment plan based on their specific symptoms, severity, and medical history rather than pursuing PRP as a primary intervention.
Treatment Options
- Topical corticosteroids
- Topical calcineurin inhibitors
- Phototherapy
- Oral immunosuppressants
- Biologics such as dupilumab
Important Considerations
- The lack of clinical evidence supporting the efficacy of PRP for eczema
- The potential risks and benefits of using PRP for eczema, which are not well established
- The importance of consulting with a dermatologist to develop an individualized treatment plan.